Company Profile

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE600.50-2.65 (-0.44 % )
PREV CLOSE (Rs.) 603.15
OPEN PRICE (Rs.) 607.90
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 600.50 (5000 )
VOLUME 53573
TODAY'S LOW / HIGH (Rs.)593.25 607.90
52 WK LOW / HIGH (Rs.)537 838
NSE600.25 -3.55 (-0.59 % )
PREV CLOSE(Rs.) 603.80
OPEN PRICE (Rs.) 606.75
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 600.25 (6550 )
VOLUME 1739942
TODAY'S LOW / HIGH(Rs.) 592.95 606.75
52 WK LOW / HIGH (Rs.)536.6 838

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.42
TTM EPS (Rs.) 27.91
P/E Ratio 21.52
Book Value (Rs.) 199.36
Face Value (Rs.) 1
MCap (Rs. in Mn) 351856.13
Price/Earning (TTM) 17.00
Price/Sales (TTM) 2.83
Price/Book (MRQ) 3.01
PAT Margin (%) 12.48
ROCE (%) 14.85
Incorporation Year : 1986

Management Info :

K Ragunathan - Chairman N Govindarajan - Managing Director

Registered Office :

Address : Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone : +91-040-66725000

Website : www.aurobindo.com

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
08Aug08-08-2019$Aurobindo Pharma reports 40% rise in Q1 consolidated net profit Aurobindo Pharma reports 40%

Aurobindo Pharma has reported results for first quarter ended June 30, 2019.

The company has reported a rise of 46.81% in its net profit at Rs 330.50 crore for the quarter under review as compared to Rs 225.12 crore for the same quarter in the previous year. Total income of the company increased by 21.37% at Rs 3,108.97 crore for Q1FY20 as compared Rs 2,561.64 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 39.53% in its net profit at Rs 635.68 crore for the quarter under review as compared to Rs 455.59 crore for the same quarter in the previous year. Total income of the company increased by 27.16% at Rs 5,460.38 crore for Q1FY20 as compared Rs 4294.00 crore for the corresponding quarter previous year.

Aurobindo Pharma has reported results for first quarter ended J..
08Aug08-08-2019$Aurobindo Pharma shines on reporting 40% rise in Q1 consolidated net profit Aurobindo Pharma shines on r

Aurobindo Pharma is currently trading at Rs. 583.80, up by 28.80 points or 5.19% from its previous closing of Rs. 555.00 on the BSE.

The scrip opened at Rs. 582.00 and has touched a high and low of Rs. 585.25 and Rs. 571.90 respectively. So far 107314 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 537.00 on 05-Aug-2019.

Last one week high and low of the scrip stood at Rs. 585.25 and Rs. 537.00 respectively. The current market cap of the company is Rs. 33983.11 crore.

The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 35.23% and 12.90% respectively.

The company has reported a rise of 46.81% in its net profit at Rs 330.50 crore for first quarter ended June 30, 2019 as compared to Rs 225.12 crore for the same quarter in the previous year. Total income of the company increased by 21.37% at Rs 3,108.97 crore for Q1FY20 as compared Rs 2,561.64 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 39.53% in its net profit at Rs 635.68 crore for the quarter under review as compared to Rs 455.59 crore for the same quarter in the previous year. Total income of the company increased by 27.16% at Rs 5,460.38 crore for Q1FY20 as compared Rs 4294.00 crore for the corresponding quarter previous year.



Aurobindo Pharma is currently trading at Rs. 583.80, up by 28.8..
05Aug08-05-2019$Aurobindo Pharma informs about analyst call Aurobindo Pharma informs abo

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that an analyst / investor call on the Unaudited Financial Results of the Company for the first quarter ended 30th June 2019 is scheduled on 8th August 2019 at 8:30 AM.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and D..
11Jul07-11-2019$Aurobindo Pharma launches Cinacalcet Hydrochloride Tablets Aurobindo Pharma launches Ci

Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets (30mg, 60mg and 90mg) at risk in the US market in accordance with the terms of settlement agreement with Amgen Inc. Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets had an annual sale of approximately $1,449 million for the twelve months ending May 2019 as per IQVIA.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets..
11Jul07-11-2019$KPI Global Infrastructure, Religare Enterprises and Aurobindo Pharma to see some action today KPI Global Infrastructure, R

KPI Global Infrastructure has signed Power Purchase Agreement (PPA) with Super Deluxe Paper Mills, Vapi for sale of 1 MW solar power for a period of 15 years under the category of Independent Power Producer (IPP).

Religare Enterprises has entered into a binding term sheet with TCG Advisory Services, Religare Finvest (RFL) and Religare Housing Development Finance Corporation (RHDFCL), whereby the company will divest its entire stake in RFL, a subsidiary of the Company, to TCG Advisory Services or any of its affiliates.

Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets (30mg, 60mg and 90mg) at risk in the US market in accordance with the terms of settlement agreement with Amgen Inc. Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets had an annual sale of approximately $1,449 million for the twelve months ending May 2019 as per IQVIA.

Premier Explosives has bagged an order from Bharat Dynamics (BDL) for supply of solid propellants for Medium Range Surface to Air Missile (MRSAM) for a value of Rs 14.99 crore (including GST) to be executed within a period of 14 months.

Trident has reported 11,702 metric tons production of Paper in June 2019. Further, chemicals production stood at 7,528 metric tons. The company’s bath linen and yarn production stood at 4,023 metric tons and 9,133 metric tons, respectively, while bed linen production stood at 1.75 million metres during June.

Bharti Airtel has partnered with Irish and India based global EdTech, Shaw Academy to offer popular online courses to its mobile customers, as part of the fast expanding range of exciting benefits under its refreshed ‘AirtelThanks program’. As part of their exclusive AirtelThanks benefits, Airtel Platinum mobile customers will now get a one year access to the entire Shaw Academy course library worth Rs 6000.

Datamatics Global Services has collaborated with Thomson Reuters to bring together TaxAnalyze, a Tax Validation tool. The product will help corporates streamline their financial information, automate tax processes and ensure seamless tax calculations. The solution is powered by Thomson Reuters ONESOURCE and Datamatics TruBI.

KPI Global Infrastructure has signed Power Purchase Agreement (..
Financials More
Rs. in Millions
QTR Jun 19 ANNUAL 19
Net Profit330515297.3
Gross Profit 4334.5 19646.2
Operating Profit 5805.525085.7
Net Sales 30788.3122578.9
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Dr. Reddys Lab (BSE)
 2554.90 (1.77%)
M.Cap ( in Cr)
42440.42
Astrazeneca Pharma I (BSE)
 1774.20 (2.41%)
M.Cap ( in Cr)
4435.50
Jenburkt Pharma (BSE)
 451.90 (6.33%)
M.Cap ( in Cr)
207.39
Alkem Laboratories (BSE)
 1768.85 (1.27%)
M.Cap ( in Cr)
21149.26
Everest Organics (BSE)
 179.15 (11.97%)
M.Cap ( in Cr)
143.32
Shareholding Pattern More
PROMOTERS 51.87 %
MUTUAL FUNDS/UTI 13.03 %
NON-INSTITUTION 12.9 %
FI/BANKS/INSURANCE 0.24 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes